1. Catalog
  2. Unmasking MASH-the silent liver disease”
Unmasking MASH-the silent liver disease”
Create Account
Availability
On-Demand
4 Courses
Cost
$0.00
Credit Offered
1 AMA PRA Category 1 Credit
7 Attendance Credits
  • Description
  • Learning Objectives
  • Faculty and Disclosures
  • Commercial Support
  • Accreditation Information
  • Privacy Policy
In 2023, a global Delphi consensus process led to a change in nomenclature from Non-Alcoholic Fatty liver disease (NAFLD) and non-alcoholic Steatohepatitis (NASH) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) (Rinella, 2023). Experts estimate a 99% overlap between patients having NAFLD and patients with MASLD, most of NAFLD guidelines would apply to patients with MASLD. New concept of Metabolic Dysfunction and Alcohol-associated steatotic Liver Disease (MetALD) in the nomenclature allow for different management approach for this subset of patients. A large overlap between type 2 Diabetes and Obesity and MASLD / MASH has been reported, making primary care an important setting for early identification and management of these conditions. Efforts are required to disseminate the new nomenclature and discuss the impact it has on the practice guidelines and clinical practice implications (Kanwal. Et al. 2023).

In 2024, The American Association for the Study of Liver Diseases (AASLD) identified MASLD/MASH as a top priority for education, based on an assessment of their members’ needs. More precisely, practice gaps and learning needs were identified regarding 1) Epidemiology of MASLD/MASH, 2) Diagnosis/Testing, incl. NITs (with pathways of care/ integration into EHRs), 3) Treatment, including current and emerging therapies, 4) Research on MASLD/MASH.

This project presents a collaborative effort between three large professional societies (AASLD, the America Academy of PAs (AAPA) and the American College of Osteopathic Family Physicians (ACOFP), with the support of a fourth collaborator, AXDEV Global Inc. (expertise in education, outcome assessment and complex project management) to develop and deploy an educational program that can reach a large audience of clinicians in the primary care setting.
Upon completion of this activity, participants should be able to:
  • Define the new nomenclature of MASLD and associated practice changes and impacts on the assessment and management of patients with Steatotic Liver Disease (SLD) patients.
  • Identifiy and screen patients at risk for SLD, using the appropriate assessment tools, and determine when specialist referral is required.
  • Develop confident and competent PCPs capable of engaging in the proactive and collaborative management of patients with MASLD and MASH.
This online educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence for Accredited Continuing Education by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty and others in the planning and control of continuing medical education (CME) activities to disclose all of their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. Conflicts, if any, are resolved through one or more processes. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Robert Fontana, MD, FAASLD
Scientific Consultant/Advisor: CymaBay, Sanofi Consulting: MasterSwitch
Research Grants: Bristol Myers-Squibb, Gilead, AbbVie, Fractyl, kezar pharmaceuticals, Miro, Takeda
Data Safety Monitoring Board: Metsera

Hilary Lois, DO:
Nothing to Disclose

Cara Orr, PA-C
Scientific Consultant/Advisor: Orderly Meds

Sarah Repking, RN, MSN, ACNP- BC
Nothing to Disclose

Niharika Samala, MBBS
Scientific Consultant/Advisor: MASH Net
Research Grants: Petauri
Speaker’s Bureau: Health Pro Match

All staff have nothing to disclose:

AAPA:
Leah Eberhardt
Daniel Pace
Eric Peterson

AASLD:
Steven Folstein
Laura Shelters

ACOFP:
Lyndsey Aspaas
Steve Legault
Paige Zelinsky

AXDEV:
Randa Dalle
Patrice Lazure
Deborah Talamonti
This activity is supported by an unrestricted educational grant from:

Boehringer-Ingelheim
Novo-Nordisk
AASLD:

The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA:

MASLD is an online CME activity that offers up to 4.0 credits of AAPA Category 1 CME of orthopaedic CME that you can access online anytime. Explore topics like orthopaedic oncology, orthopaedic infections, pediatric orthopaedics, hip and knee arthroplasty, orthopaedic fracture management, radiology, sports medicine, and more. With over two dozen expert-led sessions, this course provides practical, case-based education that you can apply directly to clinical practice. It is ideal for PAs and NPs who are new to orthopaedics, seeking a refresher, or looking to transition into this specialty.


ACOFP:

AXDEV:

.
Powered By